SCHEMBL272504

SCHEMBL272504

COc1cccc(Cn2ccc(CN3CCN(c4ccccc4)CC3)c(O)c2=O)c1

nearest known ligand 0.62

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
VEGFA P15692 3/20 0.62
EGLN1 Q9GZT9 3/20 0.62
SIGMAR1 Q99720 1/20 0.53
MAPT P10636 4/20 0.51
TSHR P16473 2/20 0.51
THRB P10828 1/20 0.51
MEN1 O00255 2/20 0.50
KMT2A Q03164 2/20 0.50
ATM Q13315 1/20 0.50
KDM4E B2RXH2 4/20 0.49
TP53 P04637 2/20 0.49
LMNA P02545 2/20 0.49
SMN1; SMN2 Q16637 2/20 0.49
HSD17B10 Q99714 1/20 0.49
GFER P55789 2/20 0.48
ALDH1A1 P00352 2/20 0.47
FAAH O00519 1/20 0.47
GAA P10253 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL272197 0.88 VEGFA (0.61) VEGFAEGLN1SIGMAR1MAPTMEN1
SCHEMBL271701 0.88 VEGFA (0.60) VEGFAEGLN1SIGMAR1MAPTMEN1
SCHEMBL17005917 0.87 VEGFA (0.60) VEGFAEGLN1SIGMAR1MAPTMEN1
SCHEMBL30402716 0.87 VEGFA (0.59) VEGFAEGLN1SIGMAR1MAPTMEN1
SCHEMBL1772095 0.87 VEGFA (0.59) VEGFAEGLN1SIGMAR1MAPTMEN1
SCHEMBL272320 0.86 VEGFA (0.83) VEGFAEGLN1TSHRKDM4EALDH1A1
SCHEMBL17005979 0.84 VEGFA (0.56) VEGFAEGLN1SIGMAR1MAPTMEN1
SCHEMBL2682460 0.83 VEGFA (0.77) VEGFAEGLN1SIGMAR1MAPTTSHR
SCHEMBL17005952 0.83 VEGFA (0.55) VEGFAEGLN1MAPTMEN1KMT2A
SCHEMBL28572828 0.81 VEGFA (0.70) VEGFAEGLN1SIGMAR1MAPTMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8133894-B2 N-benzyl-4-methyleneamino-3-hydroxy-2-pyridones AKEBIA THERAPEUTICS INC. (US) 2012-03-13 US claimed
US-20100305097-A1 N-BENZYL-4-METHYLENEAMINO-3-HYDROXY-2-PYRIDONES WARNER CHILCOTT COMPANY, LLC 2010-12-02 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100305097-A1 N-BENZYL-4-METHYLENEAMINO-3-HYDROXY-2-PYRIDONES IL17A, IFNG, CD4 VEGFA 3152/4885EGLN1 776/4885SIGMAR1 1768/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.